VOLUME 5, ISSUE 9

September 2020

Creating Change to Last a Lifetime for Childhood Cancer Awareness Month

Throughout September, the National Brain Tumor Society has recognized Childhood Cancer Awareness Month (CCAM) by honoring children that have been affected by cancer and the families that care for them, while highlighting the critical need to support research that can lead to safer and more effective treatments for our most vulnerable patients.

We've shared the stories from our NBTS community and invited you to tell your own personal story. We’ve helped people in Maryland, Southern California, and New York come together virtually to raise awareness and funds to help conquer and cure brain tumors. We've joined the conversation across social media to advocate for medical research, we’ve created change in small but mighty ways using the CCAM activities toolkit, and we even hosted a timeless virtual benefit concert from internationally acclaimed artist, Mike Massť.

Brain tumors are the leading cause of cancer-related deaths in children, as well as the most commonly diagnosed cancer in children ages 14 years old and younger. With such limited progress made in treating pediatric brain tumors, we know the time to act is now. Make a gift today and help accelerate the rate at which we discover, develop, test, and approve new treatments, while working together to advance a cure.

GIVE NOW

Get Access to Services

NBTS patient and care partner education and navigation services provide personalized support and comfort for the brain tumor community, especially in light of how COVID-19 affects the accessibility of brain tumor care.

Meditation Mondays

COVID-19: What the Brain Tumor Community Needs to Know

Personalized Support and Navigation Program

Brain Tumor Support Conversations

The Brain Tumor Experience

Clinical Trial Finder

Telehealth Resources

Watch Now:
What is Project HOPE?

An important part of CCAM is highlighting the progress being made in pediatric brain tumor research. As such, the National Brain Tumor Society is proud to announce a webinar discussing Project HOPE (High-Grade Glioma-Omics in Pediatric and Adolescent Young Adults).

Project HOPE is a transformative research project optimizing single cell sequencing to learn more about tumor growth and progression. During this conversation, Dr. Mariella Filbin, Co-Director, Pediatric Neuro-Oncology Program, Dana-Farber Boston Children's Cancer and Blood Disorder Center; Dr. W.K. Alfred Yung, Professor, Department of Neuro-Oncology, UT MD Anderson Cancer Center; and David Arons, CEO of NBTS discuss key information that the entire brain tumor community should know about this work.

Join us as we explore how this impactful research is creating change to last a lifetime.

WATCH NOW

UPCOMING EVENTS

Long Island Brain Tumor Walk
SAT, OCT 3

Race For Hope Philadelphia
SAT, OCT 10

National Brain Freeze
SAT, OCT 17

Boston Brain Tumor Walk
SUN, OCT 18

Ft. Worth Brain Tumor Walk
SAT, NOV 7

RVA Brain Tumor 5K
SAT, NOV 7

Phoenix Brain Tumor Walk
SAT, DEC 5

Florida Brain Tumor Race
SAT, DEC 5


Change

CERN Foundation Becomes A Designated Program of NBTS

Now operating as a fully-integrated, designated program of NBTS, the Collaborative Ependymoma Research Network (CERN) Foundation is carrying forward its work through the NBTS platform to advance ependymoma research toward the development of new and better treatments for this rare brain and spinal cord tumor that impacts both adults and children. The Ependymoma Fund for Research and Education is the flagship initiative to support research, advocacy, and patient education initiatives for this rare tumor.

Learn more.


Defeat

New Ependymoma Molecular Classification Updates

NBTS and the CERN Foundation hosted a virtual event on critical information about recently released ependymoma molecular classification updates. New findings, published this month, were discussed by Dr. David Ellison, Chair of Pathology at St. Jude Children’s Research Hospital; Dr. Mark Gilbert, Chief of the Neuro-Oncology Branch at the National Institutes of Health; and Kim Wallgren, Executive Director of the CERN Foundation, a program of the National Brain Tumor Society, to help educate patients and care partners on molecular classification and why it’s important to the community.

Watch now.


Connect

Double Your Impact on Promising Research

Many gliomas have a mutation to genes known as IDH1 or IDH2. Despite their prevalence, treatment attempts targeting these specific mutations have been largely unsuccessful. At Yale University, Dr. Ranjit Bindra and his team of researchers believe they’ve figured out why. NBTS is excited to announce a new $150K matching gift challenge from two anonymous donors to advance Dr. Bindra's cutting-edge research with the potential to lead to new treatments for brain tumor patients.

Learn more.

FROM THE MEDIA CENTER

National Brain Tumor Society Marks Childhood Cancer Awareness Month with Virtual Concert, Raises Awareness and Funds for Pediatric Brain Tumor Research

Build Me Up: Glioblastoma Caregiver Gets National Platform (Q&A)

NBTS Brain Tumor Clinical Trials Report: Q2 2020


Watch our channel

Connect facebook twitter youtube flickr donate Forward to a Friend
National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners. Our vision is to conquer and cure brain tumors – once and for all.
title Was this e-mail forwarded to you?
Subscribe today. Forward to a friend.
55 Chapel Street, Suite 200, Newton, MA 02458
617.924.9997 | Contact us | www.braintumor.org
Update email preferences or unsubscribe
© National Brain Tumor Society - All Rights Reserved.